Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Htg Molecular Diagnostics, Inc (HTGM)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Htg Molecular Diagnostics, Inc.
Table 2 shows the detailed insider transactions.
This company's CIK number is 1169987.
Total stock buying since 2015: $14,128,425.
Total stock sales since 2015: $5,472,640.
Total stock option exercises since 2015: $0.
Table 3. Detailed insider trading at Htg Molecular Diagnostics, Inc (HTGM)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2023-06-08 | Barat Stephen (Senior VP of Therapeutics) | Sale | 888 | .80 | 710 |
| 2019-12-26 | Johnson Tim B (Executive Chairman) | Sale | 5,718 | .72 | 4,111 |
| 2017-12-01 | Mcmeans Shaun D (VP, Finance & Admin. & CFO) | Sale | 945 | 2.11 | 1,992 |
| 2017-11-01 | Mcmeans Shaun D (VP, Finance & Admin. & CFO) | Sale | 945 | 2.26 | 2,135 |
| 2017-10-16 | Mcmeans Shaun D (VP, Finance & Admin. & CFO) | Sale | 946 | 2.27 | 2,148 |
| 2017-08-25 | Novo Holdings A/s (10% Owner) | Sale | 720,214 | 1.75 | 1,260,374 |
| 2017-08-24 | Novo Holdings A/s (10% Owner) | Sale | 382,437 | 1.91 | 730,072 |
| 2017-08-23 | Novo Holdings A/s (10% Owner) | Sale | 47,162 | 2.02 | 95,455 |
| 2017-08-22 | Novo Holdings A/s (10% Owner) | Sale | 12,641 | 2.01 | 25,408 |
| 2017-08-21 | Novo Holdings A/s (10% Owner) | Sale | 12,845 | 2.02 | 25,972 |
| 2017-08-18 | Novo Holdings A/s (10% Owner) | Sale | 55,100 | 2.10 | 115,599 |
| 2017-03-27 | Glaxosmithkline Plc | Sale | 300,000 | 10.15 | 3,045,300 |
| 2016-04-04 | Lubniewski John L (Chief Business Officer) | Sale | 87 | 2.92 | 254 |
| 2016-04-04 | Gordon Debra A (V.P. and Chief Legal Counsel) | Sale | 183 | 2.92 | 535 |
| 2016-04-04 | Mcmeans Shaun D (VP, Finance & Admin. & CFO) | Sale | 175 | 2.92 | 511 |
| 2016-04-04 | Johnson Tim B (President & CEO) | Sale | 538 | 2.92 | 1,573 |
| 2016-04-01 | Lubniewski John L (Chief Business Officer) | Sale | 709 | 2.89 | 2,048 |
| 2016-04-01 | Gordon Debra A (V.P. and Chief Legal Counsel) | Sale | 1,489 | 2.89 | 4,301 |
| 2016-04-01 | Mcmeans Shaun D (VP, Finance & Admin. & CFO) | Sale | 1,426 | 2.89 | 4,119 |
| 2016-04-01 | Johnson Tim B (President & CEO) | Sale | 4,376 | 2.89 | 12,642 |
| 2016-03-14 | Lubniewski John L (Chief Business Officer) | Sale | 113 | 2.19 | 247 |
| 2016-03-14 | Gordon Debra A (V.P. and Chief Legal Counsel) | Sale | 109 | 2.19 | 238 |
| 2016-03-14 | Roche Patrick C. (SVP Research & Development) | Sale | 111 | 2.19 | 242 |
| 2016-03-14 | Mcmeans Shaun D (VP, Finance & Admin. & CFO) | Sale | 109 | 2.19 | 238 |
| 2016-03-14 | Johnson Tim B (President & CEO) | Sale | 125 | 2.19 | 273 |
| 2016-03-11 | Lubniewski John L (Chief Business Officer) | Sale | 5,264 | 2.35 | 12,396 |
| 2016-03-11 | Gordon Debra A (V.P. and Chief Legal Counsel) | Sale | 4,215 | 2.35 | 9,926 |
| 2016-03-11 | Roche Patrick C. (SVP Research & Development) | Sale | 4,520 | 2.35 | 10,644 |
| 2016-03-11 | Mcmeans Shaun D (VP, Finance & Admin. & CFO) | Sale | 4,305 | 2.35 | 10,138 |
| 2016-03-11 | Johnson Tim B (President & CEO) | Sale | 8,154 | 2.35 | 19,202 |
| 2016-03-10 | Lubniewski John L (Chief Business Officer) | Sale | 1,512 | 2.49 | 3,764 |
| 2016-03-10 | Gordon Debra A (V.P. and Chief Legal Counsel) | Sale | 1,211 | 2.49 | 3,015 |
| 2016-03-10 | Roche Patrick C. (SVP Research & Development) | Sale | 1,298 | 2.49 | 3,232 |
| 2016-03-10 | Mcmeans Shaun D (VP, Finance & Admin. & CFO) | Sale | 1,237 | 2.49 | 3,080 |
| 2016-03-10 | Johnson Tim B (President & CEO) | Sale | 2,342 | 2.49 | 5,831 |
| 2016-03-09 | Lubniewski John L (Chief Business Officer) | Sale | 4,067 | 2.69 | 10,928 |
| 2016-03-09 | Gordon Debra A (V.P. and Chief Legal Counsel) | Sale | 3,256 | 2.69 | 8,748 |
| 2016-03-09 | Roche Patrick C. (SVP Research & Development) | Sale | 3,491 | 2.69 | 9,380 |
| 2016-03-09 | Mcmeans Shaun D (VP, Finance & Admin. & CFO) | Sale | 3,325 | 2.69 | 8,934 |
| 2016-03-09 | Johnson Tim B (President & CEO) | Sale | 6,299 | 2.69 | 16,925 |
| 2015-08-24 | Gordon Debra A (V.P. and Chief Legal Counsel) | Buy | 1,000 | 5.16 | 5,160 |
| 2015-08-24 | Johnson Tim B (President & CEO) | Buy | 1,000 | 5.34 | 5,341 |
| 2015-08-18 | Roche Patrick C. (SVP Research & Development) | Buy | 6,500 | 5.81 | 37,784 |
| 2015-08-12 | Mcmeans Shaun D (VP, Finance & Admin. & CFO) | Buy | 650 | 7.50 | 4,875 |
| 2015-08-12 | Johnson Tim B (President & CEO) | Buy | 5,000 | 7.47 | 37,340 |
| 2015-08-11 | Lubniewski John L (Chief Business Officer) | Buy | 5,000 | 7.58 | 37,925 |
| 2015-05-11 | Senour Lawrence D. (10% Owner) | Buy | 167,343 | 14.00 | 2,342,802 |
| 2015-05-11 | Fsv Ii-b Lp (10% Owner) | Buy | 102,445 | 14.00 | 1,434,230 |
| 2015-05-11 | Novo A/s (10% Owner) | Buy | 365,106 | 14.00 | 5,111,484 |
| 2015-05-11 | Glaxosmithkline Plc | Buy | 365,106 | 14.00 | 5,111,484 |
Insider trading activities including stock purchases, stock sales, and option exercises
of HTGM listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Htg Molecular Diagnostics, Inc (symbol HTGM,
CIK number 1169987) see
the Securities and Exchange Commission (SEC) website.